...
首页> 外文期刊>Lung Cancer International >Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy
【24h】

Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy

机译:晚期非小细胞肺癌患者的预后因素:患者特征和化疗类型

获取原文

摘要

Eleven prognostic factors were retrospectively analyzed in 270 newly diagnosed patients with advanced non-small-cell lung cancer including age, sex, performance status, histology, stage, smoking status, hemoglobin level, forced expiratory volume in one second (FEV1), weight loss >5% in 3 months preceding therapy, number of involved organs, and type of first-line chemotherapy. Response rate was 35.6%, and median survival was 8.2 months (95% CI, 7.8 to 8.7) for the whole group. Age ≤60 years (P=.016),FEV1≥2L(P=.03), and the use of platinum/docetaxel (P<.0001) were significantly associated with an improved survival. Histology did not affect outcome in the absence of targeted therapies.
机译:回顾性分析了270例新诊断的晚期非小细胞肺癌患者的11个预后因素,包括年龄,性别,表现状态,组织学,分期,吸烟状况,血红蛋白水平,一秒钟的强制呼气量(FEV1),体重减轻治疗前3个月内> 5%,受累器官的数量和一线化疗的类型。整个组的缓解率为35.6%,中位生存期为8.2个月(95%CI,7.8至8.7)。年龄≤60岁(P = .016),FEV1≥2L(P = .03)和使用铂/多西他赛(P <.0001)与存活率的改善显着相关。如果没有靶向治疗,组织学不会影响预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号